Drug Trial Radar · NCT03259867
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Jul 1, 2017
Primary completion
Dec 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Teclison Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Conditions
- Hepatocellular Carcinoma
- Gastric Cancer
Interventions
Nivolumab Injectable ProductDrug
a PD-1 immune check inhibitor
Trans-arterial tirapazamine embolizationCombination product
Embolization with Lipiodol and Gelfoam
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: up to 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of California, Irvine
Orange, California · Recruiting
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.